Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05832099
Other study ID # 202202092A3
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 1, 2023
Est. completion date July 31, 2026

Study information

Verified date December 2022
Source Chang Gung Memorial Hospital
Contact Chi-Cheng Chuang, M.D.
Phone +88633281200
Email ccc2915@cgmh.org.tw
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

【Background】For cranial-irradiation-naive patients with intracranial meningiomas at risk of local recurrence, the administration of conformal cranial radiotherapy can enhance tumor control in the current era of modern radiotherapeutic techniques. Life expectancy in patients with intracranial meningiomas, particularly non-malignant meningiomas (WHO grade I and II) is essentially similar to people of general population. However, RT-related neurocognitive function (NCF) sequelae are potentially and seriously a concern which should not be ignored. In terms of the natural course of cranial irradiation-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involves impairments of episodic memory, which is significantly associated with functions of the hippocampus. Additionally, the extent of changes in hippocampal volume after local irradiation may be associated with the hippocampal dosimetry. This study thus aims to investigate the potential cause-effect relationship between the hippocampal dosimetry and radiological outcomes represented by the volumetric changes regarding the contralateral hippocampus; furthermore, the correlation between radiological outcomes and neurocognitive endpoints will be examined and clarified. 【Methods】Patients with cranial-RT-naive intracranial meningiomas may be eligible and therefore enrolled in this prospective study addressing both radiological outcomes and neurocognitive endpoints. All eligible and recruited patients should receive baseline volumetric brain MRI examination and baseline neurobehavioral assessment. Subsequently, conformal cranial irradiation in the era of modern radiotherapeutic techniques (including hypofractionated stereotactic radiotherapy, proton beam therapy volumetric modulated arc therapy) will be utilized in order to reduce the dose irradiating the contralateral hippocampus and other relevant organs at risk. The prescribed dose schemes for treating patients with intracranial meningioma depend on the decision of the radiation oncologist in charge and follow the treatment guidelines at our cancer center. Accordingly, a battery of neurocognitive measures, which includes 9 standardized neuropsychological tests categorized into 5 NCF domains (e.g., executive functions, verbal & non-verbal memory, working memory, psychomotor speed, and amygdala-related emotion recognition), is used to evaluate neurocognitive performances longitudinally for our registered patients. There will be two co-primary outcome measures in the current study. The main primary outcome will be the correlation between the mean hippocampal dose and the extent of change in hippocampal volume at 6 months after the course of cranial RT. The other primary endpoint will be 6-month cognitive-deterioration-free survival. 【Expected Results】This prospective observational cohort study aims to explore and investigate the cause-effect relationship between the hippocampal dosimetry (i.e., mean dose irradiating the hippocampus, particularly the one contralateral to the lateralization of intracranial meningioma) and the extent of hippocampal atrophy signifying one of the measures regarding radiological outcomes. Simultaneously, predefined standardized neurocognitive outcome measures such as hippocampus-related memory functions and amygdala-related emotion recognition will be obtained prospectively and longitudinally in order to examine whether any meaningfully significant correlation exists between the above radiological outcome measures and neurocognitive endpoints. The mutual associations among hippocampal dosimetry, radiological outcomes including the MRI-delineated hippocampal volume, and neurocognitive endpoints including hippocampus-related verbal/non-verbal memory functions will be examined thoroughly.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 74
Est. completion date July 31, 2026
Est. primary completion date July 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients with clinically or pathologically-confirmed intracranial non-malignant meningiomas who are at least 18 years old, referred for arranging conformal radiotherapy - A Fair/good performance status superior to Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70 Exclusion Criteria: - History of prior radiotherapy delivered to brain/head region for any reason, including stereotactic radiosurgery - Patients with malignant meningiomas diagnosed pathologically (WHO grade III) - Patients with presumed clinical target volume (CTV) encompassing bilateral peri-hippocampal regions within 5 mm away from the adjacent periphery of the hippocampus - Patients whose quality of volumetric MRI fails to meet the minimal requirements for physicians to delineate the hippocampal contouring (i.e., slice thickness > 2mm)

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiation
The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)

Locations

Country Name City State
Taiwan Chang Gung Memorial Hospital Taoyuan

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Longitudinal changes in the volumes of organs at risk including the hippocampus Longitudinal changes in the volumes (cc) of the left hippocampus, right hippocampus, left amygdala, right amygdala, left thalamus, right thalamus, and so on based on volumetric MR imaging examinations baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Change in verbal memory function Change in verbal memory function related to left hippocampus from baseline to 4 months after cognition-preserving cranial RT baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Change in non-verbal memory learning Change in non-verbal memory learning associated with right hippocampus from baseline to 4 months after cognition-preserving brain RT baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Change in executive function Change in executive function related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.
Concerning the domain of executive functions generally dominated by the frontal lobes, the Modified Card Sorting Test is employed to assess both conceptual formation and mental shifting which have been documented to be the major components of executive functions.
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Change in emotion memory task Change in emotion memory tasks associated with the amygdala from baseline to 4 months after cognition-reserving cranial irradiation.
For evaluate and quantify the cognitive function of amygdala, the NCF test tailored to the emotional recognition task will be used and patients' performances will be assessed using the commercialized and computerized test included in Cambridge Cognition® package.
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Change in working memory Change in working memory related to hippocampus from baseline to 4 months after cognition-preserving cranial RT.
Working memory includes executive functions and psychomotor speed.
The neurocognitive outcome of verbal working memory was determined by the Digit Span Subtest (DS) and Spatial Span (SSP) of the Wechsler Adult Intelligence Scale- 3rd edition (WAIS-III®).
In order to indicate patients' performance on the psychomotor speed, we make use of Psychomotor Speed Index (PSI), which is derived from the composite score of Digit Symbol Coding Subtest (DSS) and Symbol Searching Subtest (SS) of the WAIS-III®.
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Longitudinal changes in the imaging biomarkers Longitudinal changes in the imaging biomarkers from DTI imaging baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Longitudinal changes in the fractional anisotropy Longitudinal changes in the fractional anisotropy (FA, unitless index between 0 and 1) from DTI imaging baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
Secondary Trajectories in the imaging biomarker Trajectories in the imaging biomarker, mean diffusivity (MD, mm squared/second) based on DTI imaging baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03180268 - Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery Phase 3
Terminated NCT00972335 - Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma Phase 2
Recruiting NCT02523014 - Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas Phase 2
Active, not recruiting NCT02974127 - Multisession Radiosurgery in Large Meningiomas
Not yet recruiting NCT02084927 - Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery Phase 1